Placeholder Banner

BIO Submits Comments on FDA Guidance: Conducting Remote Regulatory Assessments – Q&As

September 23, 2022

On Friday, September 23rd, BIO submitted comments in response to a new draft guidance describing FDA’s perspective on its use of remote regulatory assessments (RRAs). In particular, the draft guidance responded to frequently asked questions on what RRAs are, when and why FDA may use them, and how FDA may conduct them, among others. In the comment submitted, BIO expressed general support for the modernization of inspection activities and appreciation for the development of this draft guidance to assist industry with the conduct of RRAs. Given their potential benefits, BIO recommended that FDA leverage these assessments as part of its routine surveillance process. However, BIO requested further clarification on the intended scope and role of RRAs relative to pre-approval/pre-licensure inspections (PAI/PLI). Additionally, BIO recommended that the Agency clarify the similarities and differences in what an establishment might expect to happen during voluntary and mandatory RRAs. As RRAs may be more resource intensive for establishments, BIO suggested that FDA clearly explain the outcomes desired by continual use of RRAs outside public health emergencies along with metrics that could be used to evaluate impact. In addition to specific line edits, BIO also requested that FDA consider the impact and potential unintended consequences of RRAs on GxP facilities, as FDA does not currently use these assessments to indicate or recognize cGMP/GLP compliance.

Download Full Comments Below
BIO Comments_RRA Q and A_FDA 2022_D_0810
Discover More
On October 28th, BIO submitted comments to the World Health Organization on its new draft guideline containing regulatory considerations and requirements for the marketing authorization of monoclonal antibodies (mAbs) and related products based on…
On October 28th, BIO submitted comments on the ICH E11A Pediatric Extrapolation Guideline as published by the Food & Drug Administration (FDA). In the comments submitted, BIO voiced appreciation for the guideline’s clear explanation for how…
On November 1st, BIO submitted comments in response to the Food & Drug Administration’s (FDA) recent Pharmaceutical Science and Clinical Pharmacology Advisory Committee meeting. The meeting was primarily focused on two topics: the future of the…